New AI-generated COVID drug enters Phase I clinical trials: Claims to be effective against all variants
Insilico Medicine, an AI-driven biotech company, has announced its AI-designed COVID-19 drug is entering Phase I clinical trials. Promising to deliver lasting results against all variants, this could become the first viable alternative to Paxlovid. To …